Myeloma treatments have come a long way, and the outlook continues to improve. More than 90% of people respond well to their first round of treatment, and on average, people remain in remission for about four years after initial treatment. The five-year survival rate for myeloma is around 62%, and this number has been Show Full Answer
Myeloma treatments have come a long way, and the outlook continues to improve. More than 90% of people respond well to their first round of treatment, and on average, people remain in remission for about four years after initial treatment. The five-year survival rate for myeloma is around 62%, and this number has been steadily climbing as new treatments are developed. Some newer medications are so recent that long-term data isn't even available yet — which is actually an encouraging sign of how fast things are moving. While myeloma isn't considered curable for most people, the goal of treatment is to keep it in remission as long as possible. Treatment plans typically combine several approaches, such as:
- Chemotherapy to kill or slow myeloma cells
- Immunomodulatory drugs (IMiDs) to boost the immune system
- Proteasome inhibitors to trigger cancer cell death
- Corticosteroids to enhance the effects of other treatments
- Stem cell transplants to replace cancer cells with healthy ones
- CAR T-cell therapy and monoclonal antibodies for more targeted approaches
If myeloma does return after remission, there are still further treatment options available, including clinical trials testing promising new therapies. It's always worth having an open conversation with your care team about which treatments best suit your situation, including weighing the benefits against potential side effects and quality of life considerations.
July 23
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
